Author

Erin L. Sausville

Yale UniversityORCID 0000-0002-4386-703XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Approach:genetic perturbation / CRISPR· 2 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

Jason M. SheltzeriD· 3 shared Sanat Mishra· 3 shared Christopher R. VakociD· 2 shared Linda JulianiD· 2 shared Olaf KlingbeiliD· 2 shared Ryan A. HagensoniD· 2 shared Sarah L. ThompsoniD· 2 shared Aditi Swamy· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Jason M. SheltzerORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Paired CRISPR screens identify mitochondrial metabolism and UBE2H as aneuploid-specific dependencies in human cancer cell lines

Klaske M. Schukken, Saron M. Akalu, Charles Zou, Pranav K. Kandikuppa, Ryan A. Hagenson, Jessica L. Keane, Mason P. Lynch, Toyoki Yoshimoto, Olaf Klingbeil, Erin L. Sausville, Sanat Mishra, Christopher R. Vakoc, Zuzana Štorchová, Sarah J. Aitken, Jason M. Sheltzer

bioRxiv · Apr 28, 2026 · PreprintCancer Biology

A clinical-stage oncology compound selectively targets drug-resistant cancers

Kaitlin Long, Debanjan Bhattacharjee, Samuel H. Newman-Stonebraker, Simon Suhr, Brandon Q. Mercado, Emily Scheib, Anthony Tighe, Luciano Romero, Sarah L. Thompson, Erin L. Sausville, Kristen M. John, Linda Julian, Sanat Mishra, Olaf Klingbeil, Punya Gupta, , Jason M. Sheltzer

This study reveals that PAC-1, a clinical-stage oncology compound, targets drug-resistant cancers by disrupting iron homeostasis and exploiting MDR1 expression to induce iron depletion.

bioRxiv · Nov 26, 2025 · PreprintCancer Biology

On-target toxicity limits the efficacy of CDK11 inhibition against cancers with 1p36 deletions

Linda Julian, Lisa Crozier, Devon A. Lukow, Sanat Mishra, Aditi Swamy, Ryan A. Hagenson, Peter C. Sennhenn, Erin L. Sausville, Brianna E. Mendelson, Claudio Chuaqui, Lu Qiao, Anand Vasudevan, Kuan‐Ting Lin, Sonam Bhatia, Thierry Bertomeu, , Jason M. Sheltzer

This study shows CDK11 is critical for cancer cell survival and identifies 1p36 deletions as a biomarker for CDK11 inhibitor sensitivity, but on-target toxicity limits therapeutic efficacy.

bioRxiv · Aug 3, 2025 · PreprintCancer Biology